Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Terns Pharmaceuticals Inc (TERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: TERN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.8
1 Year Target Price $17.8
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.91% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 638.83M USD | Price to earnings Ratio - | 1Y Target Price 17.8 |
Price to earnings Ratio - | 1Y Target Price 17.8 | ||
Volume (30-day avg) 9 | Beta -0.05 | 52 Weeks Range 1.86 - 10.69 | Updated Date 09/17/2025 |
52 Weeks Range 1.86 - 10.69 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.97% | Return on Equity (TTM) -35.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 324518650 | Price to Sales(TTM) 302.64 |
Enterprise Value 324518650 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 87511000 | Shares Floating 57156091 |
Shares Outstanding 87511000 | Shares Floating 57156091 | ||
Percent Insiders 0.3 | Percent Institutions 99.1 |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals, Inc. is a global biopharmaceutical company founded in 2016. It focuses on developing innovative therapies for chronic liver disease, including non-alcoholic steatohepatitis (NASH), and cancer.
Core Business Areas
- NASH Programs: Development of small molecule drug candidates targeting various pathways involved in NASH, a liver disease characterized by inflammation and fat accumulation.
- Oncology Programs: Development of small molecule drug candidates targeting cancer.
Leadership and Structure
Terns is led by a management team with experience in drug development and commercialization. The organizational structure supports research and development, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- TERN-501: A thyroid hormone receptor beta (THR-u03b2) agonist being developed for NASH. Currently in clinical trials. Market share is not currently available as it is not an approved product. Competitors include Viking Therapeutics (VKTX) with VK2809, Madrigal Pharmaceuticals (MDGL) with Resmetirom, and numerous other companies developing NASH therapies.
- TERN-601: An oral small molecule GLP-1 receptor agonist for NASH and obesity. Currently in clinical trials. Market share is not currently available as it is not an approved product. Competitors include Novo Nordisk (NVO) with semaglutide (Ozempic, Wegovy), Eli Lilly (LLY) with tirzepatide (Mounjaro), and other GLP-1 agonists in development.
- TERN-701: An oral small molecule allosteric inhibitor of SRC-1. The product is currently in clinical trials for solid tumor.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The market for NASH therapies is projected to grow significantly due to the increasing prevalence of the disease.
Positioning
Terns is positioning itself as a key player in the NASH and oncology space by developing novel therapies with the potential to address unmet medical needs. Competitive advantages may include novel mechanisms of action and potentially differentiated clinical profiles.
Total Addressable Market (TAM)
The NASH market is estimated to reach tens of billions of dollars in the coming years. The oncology market is much larger. Terns is positioned to capture a portion of this TAM with successful clinical development and commercialization of its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet medical needs
- Experienced management team
- Strong intellectual property portfolio
- Pipeline diversification across NASH and oncology
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- No currently approved products
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisitions
- Positive clinical trial results leading to regulatory approval
- Growing market for NASH therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other companies developing NASH and oncology therapies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Viking Therapeutics (VKTX)
- Madrigal Pharmaceuticals (MDGL)
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
Competitive Landscape
Terns faces competition from established pharmaceutical companies and other biotechnology firms developing NASH and oncology therapies. Terns needs to demonstrate superior efficacy, safety, or convenience compared to existing and emerging treatments to gain a significant market share. Note: currently the market shares are zero because there are no FDA approved products that TERN owns and therefore have no revenues.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by pipeline advancement and clinical trial progress. Requires historical financial data for quantitative analysis.
Future Projections: Future growth depends on the successful development and commercialization of pipeline candidates. Analyst estimates are required for specific projections.
Recent Initiatives: Focus on advancing TERN-501, TERN-601 and TERN-701 through clinical trials, and expanding pipeline through strategic partnerships.
Summary
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for NASH and cancer. The company has a diverse pipeline of novel drug candidates, but faces significant risks associated with clinical development and competition. Success hinges on positive clinical trial results and strategic partnerships to advance its programs. Given its current stage, Terns needs to be diligent in capital management and clinical progression.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Terns Pharmaceuticals Inc. website
- SEC Filings
- Company Press Releases
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise. Financial metrics are subject to change based on company performance and market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.